NO175531C - Analogifremgangsmåte til fremstilling av terapeutisk aktive imidazo(4,5-b)-kinolinyloksyalkansyreamider - Google Patents

Analogifremgangsmåte til fremstilling av terapeutisk aktive imidazo(4,5-b)-kinolinyloksyalkansyreamider

Info

Publication number
NO175531C
NO175531C NO904689A NO904689A NO175531C NO 175531 C NO175531 C NO 175531C NO 904689 A NO904689 A NO 904689A NO 904689 A NO904689 A NO 904689A NO 175531 C NO175531 C NO 175531C
Authority
NO
Norway
Prior art keywords
preparation
acid amides
therapeutically active
analogous process
active imidazo
Prior art date
Application number
NO904689A
Other languages
English (en)
Other versions
NO904689D0 (no
NO175531B (no
NO904689L (no
Inventor
Nicholas Meanwell
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO904689D0 publication Critical patent/NO904689D0/no
Publication of NO904689L publication Critical patent/NO904689L/no
Publication of NO175531B publication Critical patent/NO175531B/no
Publication of NO175531C publication Critical patent/NO175531C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO904689A 1989-11-01 1990-10-30 Analogifremgangsmåte til fremstilling av terapeutisk aktive imidazo(4,5-b)-kinolinyloksyalkansyreamider NO175531C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/430,228 US4943573A (en) 1989-11-01 1989-11-01 Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility

Publications (4)

Publication Number Publication Date
NO904689D0 NO904689D0 (no) 1990-10-30
NO904689L NO904689L (no) 1991-05-02
NO175531B NO175531B (no) 1994-07-18
NO175531C true NO175531C (no) 1994-10-26

Family

ID=23706624

Family Applications (1)

Application Number Title Priority Date Filing Date
NO904689A NO175531C (no) 1989-11-01 1990-10-30 Analogifremgangsmåte til fremstilling av terapeutisk aktive imidazo(4,5-b)-kinolinyloksyalkansyreamider

Country Status (20)

Country Link
US (1) US4943573A (no)
EP (1) EP0426180A3 (no)
JP (1) JPH03169880A (no)
KR (1) KR910009705A (no)
CN (1) CN1025999C (no)
AU (1) AU639033B2 (no)
CA (1) CA2027935A1 (no)
EG (1) EG19372A (no)
FI (1) FI92697C (no)
HU (1) HU209305B (no)
IE (1) IE61579B1 (no)
IL (1) IL96167A (no)
MY (1) MY105308A (no)
NO (1) NO175531C (no)
NZ (1) NZ235868A (no)
OA (1) OA09323A (no)
PT (1) PT95765A (no)
RU (1) RU2041210C1 (no)
YU (1) YU205590A (no)
ZA (1) ZA908725B (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943573A (en) * 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5552267A (en) * 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US5208237A (en) * 1992-04-03 1993-05-04 Bristol-Meyers Squibb Company 7-oxypropylsulfonamido-imidazo[4,5-b]quinolin-2-ones
US5196428A (en) * 1992-04-03 1993-03-23 Bristol-Myers Squibb Company Imidazo[4,5-b]qinolinyl oxy alkyl ureas
US5348960A (en) * 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyl oxy alkyl tetrazolyl piperidine derivatives
US5158958A (en) * 1992-04-03 1992-10-27 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyl oxy alkyl sulfonyl piperidine derivatives
TW593317B (en) * 1993-06-21 2004-06-21 Janssen Pharmaceutica Nv Positive cardiac inotropic and lusitropic pyrroloquinolinone derivatives
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
WO1996005202A1 (fr) * 1994-08-17 1996-02-22 Nippon Hypox Laboratories Inc. Derive de l'imidazoquinoleine
US5798767A (en) * 1996-03-15 1998-08-25 Rendition, Inc. Method and apparatus for performing color space conversion using blend logic
SE9902987D0 (sv) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
US20030186963A1 (en) * 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
WO2003031432A1 (en) * 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
US7064135B2 (en) 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
EP2995619B1 (en) * 2006-08-02 2019-09-25 Cytokinetics, Inc. Certain chemical entities comprising imidazopyrimidines, compositions and methods
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US7851484B2 (en) * 2007-03-30 2010-12-14 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
GB0808967D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
GB0808947D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808952D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808968D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN108676076A (zh) 2011-03-01 2018-10-19 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
KR101951220B1 (ko) 2011-07-13 2019-02-22 싸이토키네틱스, 인코포레이티드 조합 als 치료법
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
WO2015021358A2 (en) 2013-08-09 2015-02-12 Dominique Charmot Compounds and methods for inhibiting phosphate transport
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ
WO2024149378A1 (zh) * 2023-01-13 2024-07-18 上海超阳药业有限公司 喹啉酮化合物和萘啶酮化合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932407A (en) * 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
NL7807507A (nl) * 1977-07-25 1979-01-29 Hoffmann La Roche Tricyclische verbindingen.
US4490371A (en) * 1983-02-16 1984-12-25 Syntex (U.S.A.) Inc. N,N-Disubstituted-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-B]quinazolinyl)oxyalkylamides
IL74349A (en) * 1984-02-15 1988-07-31 Syntex Inc (2-oxo-1,2,3,5-tetrahydroimidazo(2,1-b)quinazolinyl)-oxyalkylamides,their preparation and pharmaceutical compositions containing them
US4668686A (en) * 1985-04-25 1987-05-26 Bristol-Myers Company Imidazoquinoline antithrombrogenic cardiotonic agents
US4775674A (en) * 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
US4701459A (en) * 1986-07-08 1987-10-20 Bristol-Myers Company 7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation
US4943573A (en) * 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility

Also Published As

Publication number Publication date
AU639033B2 (en) 1993-07-15
EP0426180A2 (en) 1991-05-08
RU2041210C1 (ru) 1995-08-09
JPH03169880A (ja) 1991-07-23
EG19372A (en) 1994-12-30
ZA908725B (en) 1991-07-31
AU6567990A (en) 1991-05-23
HU209305B (en) 1994-04-28
FI92697B (fi) 1994-09-15
US4943573A (en) 1990-07-24
MY105308A (en) 1994-09-30
KR910009705A (ko) 1991-06-28
NO904689D0 (no) 1990-10-30
IE61579B1 (en) 1994-11-16
FI92697C (fi) 1994-12-27
HUT56102A (en) 1991-07-29
FI905326A0 (fi) 1990-10-29
IE903923A1 (en) 1991-05-08
CN1051359A (zh) 1991-05-15
IL96167A (en) 1994-11-11
CA2027935A1 (en) 1991-05-02
PT95765A (pt) 1991-09-13
OA09323A (en) 1992-09-15
NZ235868A (en) 1993-12-23
HU906977D0 (en) 1991-05-28
NO175531B (no) 1994-07-18
IL96167A0 (en) 1991-07-18
CN1025999C (zh) 1994-09-28
YU205590A (sh) 1992-09-07
EP0426180A3 (en) 1992-01-08
NO904689L (no) 1991-05-02

Similar Documents

Publication Publication Date Title
NO175531C (no) Analogifremgangsmåte til fremstilling av terapeutisk aktive imidazo(4,5-b)-kinolinyloksyalkansyreamider
NO179584C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-acylaminotiazoler
NO180586C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive substituerte imidazoler
NO175978C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive bis-aza-bicykliske forbindelser
NO178619C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive di-t-butylfenoler
FI104174B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten, 1,4-dihydro-4-okso-3-kinoliinikarboksyylihapon 7-[S,S]-2,8-diatsabisyklo[4.3.0]nonaani-isomeeriven valmistamiseksi
FI875235A (fi) Menetelmä valmistaa terapeuttisesti aktiivisia tetrahydro(imidatsolyylimetyyli)-4H-karbatsol-4-oneja
NO175100C (no) Analogifremgangsmåte til fremstilling av terapeutisk aktive 4(3H)-pteridinoner
NO176273C (no) Analogifremgangsmåte for fremstilling av aktive substituerte benzamider
FI871087A (fi) Menetelmä terapeuttisesti aktiivisten 1,2,3,4-tetrahydro-3-karbamoyyli-2-tiokso/okso-5-pyrimidiinikarboksyylihappojohdannaisten valmistamiseksi
FI880467A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten substituoitujen 3,4-dihydro-2H-bentsopyraanien valmistamiseksi
NO177096C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive, substituerte isokinoliner
FI892684A (fi) Menetelmä terapeuttisesti aktiivisten 4-okso-imidatso/1,5-a/kinoksaliinijohdannaisten valmistamiseksi
NO174203C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive
NO174774C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive benzodiazepiner
FI903077A0 (fi) Menetelmä valmistaa terapeuttisesti aktiivisia R(-)-3-kinuklidinolijohdannaisia
FI100799B (fi) Menetelmä terapeuttisesti aktiivisten tetraliinijohdannaisten valmista miseksi
FI901883A0 (fi) Menetelmä terapeuttisesti vaikuttavien 2-substituoitujen N,N'-ditrimetoksibentsoyylipiperatsiinien valmistamiseksi
NO172495C (no) Fremgangsmaate for fremstilling av terapeutisk aktive, ikke-mettede aminosyreforbindelser
HU908400D0 (en) Process for the production of imidazo(4,5-c)pyridine derivatives and medical preparations containing these compounds as active agents
FI900145A (fi) Menetelmä farmaseuttisesti käyttökelpoisten 1,1-diokso-kefem-4-karbotiolihappojohdannaisten valmistamiseksi
FI93216C (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 1,3-dioksaanialkeenihappojohdannaisten valmistamiseksi
NO176180C (no) Analogifremgangsmåte for fremstilling av nye terapeutisk aktive 2-karbonyl-substituerte N,N-di(trimetoksybenzoyl) piperanziner
FI912363A (fi) Menetelmä terapeuttisesti käyttökelpoisten -oksopyrrolo/2,3-b/indolietikkahappoestereiden ja -amidien valmistamiseksi
NO174887C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive aryl- alkyl-pyrrol-2-carboxylsyreforbindelser